株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

腫瘍アブレーションの世界市場:市場分析、企業プロファイル、市場規模、市場シェア、成長、動向、市場予測

Global Tumor Ablation Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

発行 Data Bridge Market Research Private Limited 商品コード 587832
出版日 ページ情報 英文 350 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.97円で換算しております。
Back to Top
腫瘍アブレーションの世界市場:市場分析、企業プロファイル、市場規模、市場シェア、成長、動向、市場予測 Global Tumor Ablation Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024
出版日: 2017年09月01日 ページ情報: 英文 350 Pages
概要

当レポートでは、腫瘍アブレーションの世界市場を調査し、市場の概要、種類・腫瘍・エンドユーザー・地域別の市場動向、市場規模の推移と予測、市場促進要因ならびに市場機会・課題の分析、市場シェア、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 市場概要

第4章 市場概要

  • 市場概要
  • 重要考察
  • 市場促進要因、市場機会、課題
  • 主な調査結果
  • 市場動向と今後期待される新技術

第5章 腫瘍アブレーションの世界市場:種類別

  • 市場概要
  • 腫瘍アブレーションシステム
    • ラジオ波(高周波)アブレーション
    • マイクロ波アブレーション
    • 高密度焦点式超音波(HIFU)アブレーション
    • レーザーアブレーション
    • 冷凍アブレーション
  • 画像誘導機器
  • 付属品

第6章 腫瘍アブレーションの世界市場:腫瘍別

  • 市場概要
  • 肝癌
  • 脳腫瘍
  • 肺癌
  • 骨肉腫
  • 腎癌
  • 膵癌
  • 乳癌

第7章 腫瘍アブレーションの世界市場:エンドユーザー別

  • 市場概要
  • 病院
  • 診療所
  • その他

第8章 腫瘍アブレーションの世界市場:エンドユーザー別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • その他の地域
  • 主要国の分析

第9章 競合情勢

  • 全体:企業の市場シェア
  • 北米:企業の市場シェア
  • 欧州:企業の市場シェア
  • アジア太平洋:企業の市場シェア
  • 合併・買収
  • 新製品の開発・承認
  • 事業拡張
  • 規制環境の変化
  • パートナーシップ・その他の戦略動向

第10章 企業プロファイル

  • MEDTRONIC
  • GALIL MEDICAL, INC.
  • PERSEON CORPORATION
  • NEUWAVE MEDICAL, INC.
  • KONINKLIJKE PHILIPS N.V.
  • INTIO INC.
  • MERMAID MEDICAL A/S
  • SONACARE MEDICAL, LLC
  • DFINE, INC.
  • MISONIX, INC.
  • BVM MEDICAL LIMITED
  • ANGIODYNAMICS, INC.
  • COMSOL INC.
  • BOSTON SCIENTIFIC CORPORATION
  • EDAP TMS S.A.
  • HEALTHTRONICS, INC.

第11章 付録

第12章 Data Bridge Market Researchについて

目次

Title:
Global Tumor Ablation market
By Type (Tumor Ablation Systems {Radio Frequency Ablation System, Microwave Ablation System, Cryoablation, High Intensity Focused Ultrasound , Laser Ablation System}, Image Guidance Products, Accessories), By Cancer Type (Liver Cancer, Brain Cancer, Lung Cancer, Bone Cancer, Kidney Cancer, Pancreatic Cancer, Breast Cancer, Others), By Mode of Treatment (Surgical, Laparoscopic, Percutaneous), By End User (Hospitals, Oncology Clinics, Others), By Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2024.

The Global Tumor Ablation Market is accounted to reach USD 3,495.0 million by 2024 from USD 1,669.7 million in 2016,it is growing at a CAGR of 9.8% in the forecast period 2017 to 2024.

The major factors contributing to the growth of the market includes incidences of cancer patients, increase in the number of hospitals, ablation and surgical centers, technological advancement in ablation devices.

The key market players for Global Tumor Ablation Market are listed below:

  • Boston Scientific Corporation
  • Abbott
  • Galil Medical Inc.,
  • Perseon Corporation,
  • NeuWave Medical, Inc.,
  • Koninklijke Philips N.V.,
  • INTIO Inc.,
  • Mermaid Medical A/S,
  • SonaCare Medical,
  • LLC, DFINE, Inc.,
  • Misonix,
  • BVM Medical Limited,
  • AngioDynamics,
  • COMSOL Inc,
  • EDAP TMS,
  • HealthTronics, Inc.

The market is further segmented into:

  • Type
  • Application
  • End User
  • Geography

The global tumor ablation market is segmented on the basis of type, cancer type, mode of treatment, end user, and geography. On the basis of type, the market is segmented into three major segments which include tumor ablation systems, image guidance products, and accessories.

In 2017, the Tumor Ablation Systems market segment is expected to dominate the market with 69.2%. Tumor Ablation Systems is further sub segmented into radio frequency ablation system (RFA), microwave ablation system, cryoablation, high intensity focused ultrasound and laser ablation system. In 2017, radio frequency ablation system (RFA) market segment is expected to dominate the market with 53.8%.

Based on cancer type, the market is segmented into eight major segments which include liver cancer, brain cancer, lung cancer, bone cancer, kidney cancer, pancreatic cancer, breast cancer and others, The lung cancer market is expected to grow at the highest CAGR 10.7% in the forecast period of 2017 to 2024.

Based on mode of treatment, the global tumor ablation market is segmented into surgical, laproscopic and percutaneous. The Surgical is projected to witness higher growth during the forecast period., The laparoscopic market is expected to grow at the highest CAGR 10.8% in the forecast period of 2017 to 2024.

Based on end users, the market is segmented into hospital, oncology clinics, and others. In 2017, the hospital market segment is expected to dominate the market. with a share of 68.3%.

Based on geography, the Global Tumor Ablation market is segmented into geographical regions, such as,

  • North America,
  • Europe,
  • Asia-Pacific,
  • South America
  • Middle East & Africa

Covered in this report:

The report covers the present scenario and the growth prospects of the Global Tumor Ablation market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

1. INTRODUCTION

  • 1.1. OVERVIEW OF THE TUMOUR ABLATION MARKET
  • 1.2. MARKET SEGMENTATION & COVERAGE

2. RESEARCH METHODOLOGY

  • 2.1. KEY TAKEAWAYS
  • 2.2. ARRIVING AT THE TUMOUR ABLATION MARKET SIZE
    • 2.2.1. MARKET CRACKDOWN APPROACH
    • 2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
    • 2.2.3. DATA TRIANGULATION
    • 2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
    • 2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
    • 2.2.6. PORTER'S FIVE FORCES MATRIX
    • 2.2.7. PEST ANALYSIS
    • 2.2.8. EPIDEMIOLOGY FORECASTING MODELS
  • 2.3. ASSUMPTIONS

3. MARKET LANDSCAPE SUMMARY

4. MARKET OVERVIEW

  • 4.1. OVERVIEW
  • 4.2. TUMOUR ABLATION MARKET: KEY PRIMARY INSIGHTS
  • 4.3. DRIVERS, OPPORTUNITIES AND THREAT ANALYSIS MATRIX
  • 4.4. KEY MARKET FINDINGS
  • 4.5. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

5. TUMOUR ABLATION MARKET, BY TYPE

  • 5.1. OVERVIEW
  • 5.2. TUMOUR ABLATION SYSTEMS
    • 5.2.1. RADIO FREQUENCY ABLATION SYSTEM (RFA)
    • 5.2.2. MICROWAVE ABLATION SYSTEM
    • 5.2.3. HIGH FREQUENCY FOCUSED ULTRASOUND ABLATION SYSTEM (HIFU)
    • 5.2.4. LASER ABLATION SYSTEM
    • 5.2.5. CRYOABLATION
  • 5.3. IMAGE GUIDANCE PRODUCTS
  • 5.4. ACCESSORIES

6. TUMOUR ABLATION MARKET, BY CANCER TYPE

  • 6.1. OVERVIEW
  • 6.2. LIVER CANCER
  • 6.3. BRAIN CANCER
  • 6.4. LUNG CANCER
  • 6.5. BONE CANCER
  • 6.6. KIDNEY CANCER
  • 6.7. PANCREATIC CANCER
  • 6.8. BREAST CANCER
  • 6.9. OTHERS

7. TUMOR ABLATION MARKET, BY END-USER

  • 7.1. OVERVIEW
  • 7.2. HOSPITALS
  • 7.3. ONCOLOGY CLINICS
  • 7.4. OTHERS

8. TUMOUR ABLATION MARKET, BY GEOGRAPHY

  • 8.1. COUNTRYWISE TUMOUR ABLATION MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
    • 8.1.1. NORTH AMERICA
      • 8.1.1.1. U.S.
      • 8.1.1.2. CANADA
      • 8.1.1.3. MEXICO
    • 8.1.2. EUROPE
      • 8.1.2.1. GERMANY
      • 8.1.2.2. FRANCE
      • 8.1.2.3. U.K.
      • 8.1.2.4. ITALY
      • 8.1.2.5. SPAIN
      • 8.1.2.6. RUSSIA
      • 8.1.2.7. TURKEY
      • 8.1.2.8. BELGIUM
      • 8.1.2.9. NETHERLANDS
      • 8.1.2.10. SWITZERLAND
      • 8.1.2.11. REST OF EUROPE
    • 8.1.3. ASIA-PACIFIC (APAC)
      • 8.1.3.1. JAPAN
      • 8.1.3.2. CHINA
      • 8.1.3.3. SOUTH KOREA
      • 8.1.3.4. INDIA
      • 8.1.3.5. AUSTRALIA
      • 8.1.3.6. SINGAPORE
      • 8.1.3.7. THAILAND
      • 8.1.3.8. MALAYSIA
      • 8.1.3.9. REST OF APAC
    • 8.1.4. LATIN AMERICA
      • 8.1.4.1. BRAZIL
      • 8.1.4.2. REST OF LATIN AMERICA
    • 8.1.5. REST OF THE WORLD
  • 8.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

9. TUMOUR ABLATION MARKET: COMPETITIVE LANDSCAPE

  • 9.1. GLOBAL TUMOUR ABLATION MARKET: COMPANY SHARE ANALYSIS
  • 9.2. NORTH AMERICA TUMOUR ABLATION MARKET: COMPANY SHARE ANALYSIS
  • 9.3. EUROPE TUMOUR ABLATION MARKET: COMPANY SHARE ANALYSIS
  • 9.4. APAC TUMOUR ABLATION MARKET: COMPANY SHARE ANALYSIS
  • 9.5. MERGERS & ACQUISITIONS
  • 9.6. NEW PRODUCT DEVELOPMENT & APPROVALS
  • 9.7. EXPANSIONS
  • 9.8. REGULATORY CHANGES
  • 9.9. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

10. TUMOUR ABLATION MARKET, COMPANY PROFILES

  • 10.1. MEDTRONIC
    • 10.1.1 OVERVIEW
    • 10.1.2 SWOT ANALYSIS
    • 10.1.3 PRODUCT PORTFOLIO
    • 10.1.4 REVENUE ANALYSIS
    • 10.1.5 ANALYSTS VIEW
  • 10.2. GALIL MEDICAL, INC.
    • 10.2.1 OVERVIEW
    • 10.2.2 SWOT ANALYSIS
    • 10.2.3 PRODUCT PORTFOLIO
    • 10.2.4 REVENUE ANALYSIS
    • 10.2.5 ANALYSTS VIEW
  • 10.3 PERSEON CORPORATION
    • 10.3.1 OVERVIEW
    • 10.3.2 SWOT ANALYSIS
    • 10.3.3 PRODUCT PORTFOLIO
    • 10.3.4 REVENUE ANALYSIS
    • 10.3.5 ANALYST VIEW
  • 10.4 NEUWAVE MEDICAL, INC.
    • 10.4.1 OVERVIEW
    • 10.4.2 SWOT ANALYSIS
    • 10.4.3 PRODUCT PORTFOLIO
    • 10.4.4 REVENUE ANALYSIS
    • 10.4.5 ANALYSTS VIEW
  • 10.5. KONINKLIJKE PHILIPS N.V.
    • 10.5.1 OVERVIEW
    • 10.5.2 SWOT ANALYSIS
    • 10.5.3 PRODUCT PORTFOLIO
    • 10.5.4 REVENUE ANALYSIS
    • 10.5.5 ANALYSTS VIEW
  • 10.6. INTIO INC.
    • 10.6.1 OVERVIEW
    • 10.6.2 SWOT ANALYSIS
    • 10.6.3 PRODUCT PORTFOLIO
    • 10.6.4 REVENUE ANALYSIS
    • 10.6.5 ANALYSTS VIEW
  • 10.7. MERMAID MEDICAL A/S
    • 10.7.1 OVERVIEW
    • 10.7.2 SWOT ANALYSIS
    • 10.7.3 PRODUCT PORTFOLIO
    • 10.7.4 REVENUE ANALYSIS
    • 10.7.5 ANALYSTS VIEW
  • 10.8. SONACARE MEDICAL, LLC
    • 10.8.1 OVERVIEW
    • 10.8.2 SWOT ANALYSIS
    • 10.8.3 PRODUCT PORTFOLIO
    • 10.8.4 REVENUE ANALYSIS
    • 10.8.5 ANALYSTS VIEW
  • 10.9. DFINE, INC.
    • 10.9.1. OVERVIEW
    • 10.9.2. SWOT ANALYSIS
    • 10.9.3. PRODUCT PORTFOLIO
    • 10.9.4. REVENUE ANALYSIS
    • 10.9.5. ANALYSTS VIEW
  • 10.10. MISONIX, INC.
    • 10.10.1. OVERVIEW
    • 10.10.2. SWOT ANALYSIS
    • 10.10.3. PRODUCT PORTFOLIO
    • 10.10.4. REVENUE ANALYSIS
    • 10.10.5. ANALYSTS VIEW
  • 10.11. BVM MEDICAL LIMITED
    • 10.11.1. OVERVIEW
    • 10.11.2. SWOT ANALYSIS
    • 10.11.3. PRODUCT PORTFOLIO
    • 10.11.4. REVENUE ANALYSIS
    • 10.11.5. ANALYSTS VIEW
  • 10.12. ANGIODYNAMICS, INC.
    • 10.12.1. OVERVIEW
    • 10.12.2. SWOT ANALYSIS
    • 10.12.3. PRODUCT PORTFOLIO
    • 10.12.4. REVENUE ANALYSIS
    • 10.12.5. ANALYSTS VIEW
  • 10.13. COMSOL INC.
    • 10.13.1. OVERVIEW
    • 10.13.2. SWOT ANALYSIS
    • 10.13.3. PRODUCT PORTFOLIO
    • 10.13.4. REVENUE ANALYSIS
    • 10.13.5. ANALYSTS VIEW
  • 10.14. BOSTON SCIENTIFIC CORPORATION
    • 10.14.1. OVERVIEW
    • 10.14.2. SWOT ANALYSIS
    • 10.14.3. PRODUCT PORTFOLIO
    • 10.14.4. REVENUE ANALYSIS
    • 10.14.5. ANALYSTS VIEW
  • 10.15. EDAP TMS S.A.
    • 10.10.1. OVERVIEW
    • 10.10.2. SWOT ANALYSIS
    • 10.10.3. PRODUCT PORTFOLIO
    • 10.10.4. REVENUE ANALYSIS
    • 10.10.5. ANALYSTS VIEW
  • 10.16. HEALTHTRONICS, INC.
    • 10.11.1. OVERVIEW
    • 10.11.2. SWOT ANALYSIS
    • 10.11.3. PRODUCT PORTFOLIO
    • 10.11.4. REVENUE ANALYSIS
    • 10.11.5. ANALYSTS VIEW

11. APPENDIX

  • 11.1. RELATED REPORTS
  • 11.2. CUSTOMIZABLE OPTIONS
  • 11.3. SOURCE SHEET
  • 11.4. BIBLIOGRAPHY

12. ABOUT DATA BRIDGE MARKET RESEARCH

Back to Top